Canada markets close in 44 minutes

Qualigen Therapeutics Inc (7R9.DU)

Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
Add to watchlist
0.2540-0.0040 (-1.55%)
At close: 07:57PM CEST
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2023-12-31
2022-12-31
2021-12-31
Total Revenue
0
0
0
5,654
Cost of Revenue
-
-
4,303
4,332
Gross Profit
-
-
680.801
1,321
Operating Expenses
Research Development
5,209
5,209
4,486
11,717
Selling General and Administrative
6,096
6,096
10,275
12,268
Total Operating Expenses
11,305
11,305
14,761
23,984
Operating Income or Loss
-11,305
-11,305
-14,761
-22,663
Interest Expense
1,525
1,525
34.397
-
Total Other Income/Expenses Net
349.776
349.776
907.203
4,729
Income Before Tax
-12,480
-12,480
-13,888
-17,892
Income Tax Expense
-4.793
-4.793
6.548
5.427
Income from Continuing Operations
-12,475
-12,475
-13,894
-17,897
Net Income
-13,417
-13,417
-18,641
-17,897
Net Income available to common shareholders
-13,417
-13,417
-18,641
-17,897
Basic EPS
-3.73
-2.65
-4.86
-6.10
Diluted EPS
-3.73
-2.65
-4.86
-6.10
Basic Average Shares
4,820
5,073
3,840
2,933
Diluted Average Shares
4,820
5,073
3,840
2,933